NCT02400437View on ClinicalTrials.gov

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Ixazomib

Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

DRUG

Dexamethasone

Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

DRUG

Rituximab

Doses given on Day 1 of induction and maintenance cycles.

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER